AUSTIN, Texas--(BUSINESS WIRE)--Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, announced today that it has performed computer-based sequence analysis of the U.S. swine flu patient isolates and compared them to the primer sequences of the Company’s xTAG RVP assay. In the interest of providing information to its customers and to public health labs, Luminex is reporting these interim computer-based results and will provide further updates once actual patient samples have been tested with the RVP assay.
